LQDA

54.3903.96%
JC

Joanna Caroline Horobin

Independent Director

Dr. Joanna Caroline Horobin, M.B., Ch.B., served as Non-Executive Chairman at iOnctura SA since May 27, 2020. She served as an Independent Director at Vyant Bio, Inc. since March 30, 2021 until December 2023. She serves as Director at iOnctura SA since 2020. Dr. Horobin has been an Independent Director at Liquidia Corporation (formerly known as Liquidia Technologies, Inc.) since October 2019. She served as the Advisor of Aceragen, Inc. (formerly known as Idera Pharmaceuticals, Inc.) since July 31, 2019 and served as its Chief Medical Officer and Senior Vice President since November 30, 2015 until July 31, 2019. Dr. Horobin served as an Independent Director at Kymera Therapeutics, Inc. since May 2018 until June 18, 2024. Dr. Horobin served as a Senior Advisor of Verastem, Inc., since July 1, 2015 until December 1, 2015. Dr. Horobin served as the Chief Medical Officer at Verastem, Inc. from September 2012 to July 1, 2015. Dr. Horobin has comprehensive experience within the biopharmaceutical industry. Dr. Horobin served as the President of Syndax Pharmaceuticals, Inc. from September 2006 to September 2012 and served as its Chief Executive Officer since September 2006 until April 2012. Dr. Horobin served as Member of Scientific Advisory Board at Kymera Therapeutics, Inc. since April 2018. Dr. Horobin was an Entrepreneur-in-Residence of MPM Capital. She served as Chief Executive Officer of U3 Pharma GmbH. Dr. Horobin served as an Executive Vice President of Commercial Development of CASI Pharmaceuticals, Inc. She served as the Chief Operating Officer of CombinatoRx Inc. She served as Vice President of Oncology at Aventis Inc. She has developed, launched and marketed a series of innovative medicines, including three blockbuster drugs: Augmentin?, Lovenox? and Taxotere?. Dr. Horobin has held several roles of increasing responsibility at global pharmaceutical companies such as Rh?ne Poulenc Rorer (now Sanofi) where she led the global launch of Taxotere? (docetaxel) in breast cancer and Campto/Camptosar? (CPT11) for colorectal cancer. She also led a successful joint venture with Chugai to launch Granocyte? (lenograstim) and played significant leadership roles in the approvals of several successful products. Dr. Horobin had been Independent Director of Nordic Nanovector ASA since October 12, 2016. Dr. Horobin serves as a member of the board of directors of Kynera Therapeutics Inc. Dr. Horobin played significant leadership roles in the approvals of Celectol(R), temocillin, Bactroban(R) and Relafen(R)/Reliflex. She serves as Director of Nascent Pharmaceuticals Inc. She joined the pharma industry, first at Beecham Pharmaceuticals (now GSK), in 1982 and her initial clinical development roles resulted in the development and launch of 8 products in the anti-infective, cardiovascular and anti-inflammatory categories. Whilst at Rhone Poulenc Rorer (now Sanofi), in France and USA, she shifted to cancer drug development which has been her major career focus. She served as Director and Member of Advisory Board of The Cramer Productions Company, Inc. She served as a Member of Scientific Advisory Board of Zalicus Inc. (alternate name: CombinatoRx Inc.). She served as a Director of Syndax Pharmaceuticals Inc. She gained Membership of the Royal College of General Practitioners in the UK, as well holding the Diploma of Pharmaceutical Medicine from the Royal College of Physicians in the UK. Dr. Horobin received her Medical Degree from the University of Manchester in the UK and holds the Diploma of Pharmaceutical Medicine from the Royal College of Physicians.

Positions